Myomo (MYO)
Custom powered arm-and-hand braces controlled by remaining muscle signals.
Something off on this page? Send us feedback.
Sells custom-built powered MyoPro braces that interpret users’ remaining muscle signals to assist weakened or partially paralyzed arms and hands. Revenue combines direct insurer billing with wholesale sales to O&P practices, VA providers, and international accounts, making reimbursement authorization and delivery central to the business.
Designs and custom-fabricates the MyoPro platform, a powered arm-and-hand brace for people with upper-limb weakness or paralysis. Surface sensors interpret remaining muscle signals, then software and motors assist elbow and hand movement. The platform includes Motion W, Motion G, MyoCare training and support, MyoGames practice, MARK2 clinical evaluation, and a connected-care application.
Sells mainly through direct billing, alongside O&P practices, Veterans Health Administration providers, and international distributors. The United States is its principal market and Germany its only individually material foreign market. Its clinical operation evaluates patients, secures insurance authorization, customizes and fits the brace, trains users, and provides follow-up. Revenue timing depends on authorization, delivery, and payer adjudication; the business relies on a single product family, reimbursement coverage, regulated manufacturing, and specialized suppliers.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $13.5M · Total debt $20.1M · Total assets $35.3M · Shareholders' equity $5.8M
- Revenue
- $11.7M
- Operating income
- −$2.3M
- Net income
- −$4.0M
No dividends on record.
| Institutions | 30.75% | 12.18M shares | |
|---|---|---|---|
| 81 holders · as of Jun 30, 2026 | |||
| Insiders | 6.57% | 2.60M shares | |
| 6 holders · as of Sep 14, 2026 | |||
| Other | 62.68% | 24.83M shares | |
| remainder | |||
39.61M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Rosalind Advisors, Inc.Institution | 9.18% | 3.64M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.13% | 1.64M | as of Jun 30, 2026 |
Paul R. GudonisInsiderdirector, officer: Chief Executive Officer | 3.62% | 1.43M | filed Aug 11, 2026 |
AQR Capital Management LLCInstitution | 2.34% | 928,268 | as of Jun 30, 2026 |
Jefferies Financial Group Inc.Institution | 1.78% | 704,275 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 11, 2026 | Harry Kovelman | officer: Chief Medical Officer | −15,488 | $1.27 |
| Sep 2, 2026 | Milton Mayo Morris | director | −15,000 | $1.41 |
| Aug 20, 2026 | Harry Kovelman | officer: Chief Medical Officer | −34,750 | $1.73 |
- Mobia Medical
Stroke-recovery pathway rival for chronic upper-limb impairment.
- Lifeward
Emerging powered upper-body orthosis challenger in stroke care.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Myomo | $1.65 | +4.78% | $60.7M | — | — | 1.4 | +21.3% |
| Mobia Medical | $9.57 | −1.44% | $322.8M | — | — | — | — |
| Lifeward | $7.09 | +1.29% | $11.3M | — | — | 0.5 | +15.7% |
| Median | — | — | 0.5 | +15.7% |